白雲山(00874.HK):千金保孕丸新增小蜜丸規格獲國家藥監局批準
格隆匯7月22日丨白雲山(00874.HK)發佈公告,近日,公司子公司廣州白雲山陳李濟藥廠有限公司(以下簡稱“陳李濟藥廠”)收到國家藥監局簽發的《藥品補充申請批準通知書》。
陳李濟藥廠於2024年7月9日向國家藥監局遞交本藥品補充申請,於2024年8月8日獲得受理。申請變更千金保孕丸藥品規格。千金保孕丸功能主治:養血安胎。用於胎動漏血,妊娠腰痛,預防流產。該藥品是陳李濟藥廠獨家品種。陳李濟藥廠本次獲得千金保孕丸《藥品補充申請批準通知書》,是在原大蜜丸規格的基礎上新增小蜜丸規格。小蜜丸服用方便,口感優化,有利於提升該產品的市場競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.